Trial reportObesity surgery2026
Quality of Life Two Years After Gastric Bypass with Long vs. Short Biliopancreatic Limb: Results from the Randomized BPG-1 Multicenter Trial.
Trial report in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRoux-en-Y gastric bypass (RYGB) configurations vary, and recent evidence suggests that longer biliopancreatic limbs (BPL) may influence postoperative outcomes.
objectiveTo assess whether a longer BPL in RYGB improves both weight loss and quality of life (QoL) over a two-year follow-up.
methodsA multicenter, randomized controlled trial (RCT) comparing two groups: 150 cm BPL/70 cm Alimentary Limb (AL) vs. 70 cm BPL/150 cm AL. QoL was measured using the Bariatric Analysis and Reporting Outcome System (BAROS) score at 12 and 24 months.
results98 patients were included. The long-BPL group was associated with significantly higher total BAROS scores at both 12 and 24 months, with a clinically relevant moderate-to-large effect size at 24 months. A greater proportion of participants in the long-BPL group achieved “excellent” BAROS outcomes. Weight loss and remission of associated diseases were superior in the long-BPL group, while complication rates were comparable. The QoL subscore showed consistent advantages for this long-BPL group, particularly in self-esteem, physical activity, social interactions, and sexual well-being. Differences in total BAROS scores were primarily driven by greater weight loss and remission of related diseases. In the small subgroup without preoperative comorbidities, no significant differences were observed in exploratory analyses.
conclusionRYGB with a long BPL was associated with higher short- and mid-term composite outcomes, including greater weight loss and enhanced patient-reported QoL, compared with a shorter BPL configuration. Observed QoL differences appear related to weight-loss trajectories rather than an independent limb-length effect. Longer-term follow-up is ongoing to assess durability.
Indexed as
Identifiers
41984306What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.